Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.44 -1.81 (-3.68%)
Streaming Delayed Price Updated: 10:58 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
News headline image
Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition ↗
Sanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3... 
Via Benzinga
News headline image
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
From Vigil Neuroscience, Inc.
Via GlobeNewswire
News headline image
Price Over Earnings Overview: Sanofi ↗
 
Via Benzinga
News headline image
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
SANOFI-ADR (NASDAQ:SNY) – A Reliable Dividend Stock with Strong Fundamentals ↗
SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors. 
Via Chartmill
News headline image
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
News headline image
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit ↗
Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial. 
Via Benzinga
Topics Lawsuit
News headline image
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why ↗
Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations. 
Via Benzinga
News headline image
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma ↗
AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients. 
Via Benzinga
News headline image
SANOFI-ADR (NASDAQ:SNY): A Strong Growth Stock with Technical Breakout Potential ↗
SANOFI-ADR (NASDAQ:SNY): A Strong Growth Stock with Technical Breakout Potential 
Via Chartmill
News headline image
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit ↗
Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed. 
Via Benzinga
News headline image
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed ↗
Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated. 
Via Investor's Business Daily
Topics Earnings Government
News headline image
Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. ↗
Why the dividend investor may take a look at SANOFI-ADR (NASDAQ:SNY). 
Via Chartmill
News headline image
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal ↗
Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study ↗
Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline. 
Via Benzinga
News headline image
How Do Investors Really Feel About Sanofi? ↗
 
Via Benzinga
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
News headline image
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now? ↗
Via The Motley Fool
Topics Economy Government World Trade
News headline image
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst ↗
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities. 
Via Benzinga
Topics World Trade
News headline image
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday? ↗
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response rates and reduced disease flares. 
Via Benzinga
News headline image
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
News headline image
FDA Approves Sanofi's Hemophilia Drug ↗
FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Don't overlook SANOFI-ADR (NASDAQ:SNY)—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
Discover SANOFI-ADR, an undervalued stock. NASDAQ:SNY showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.